Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Biohaven Ltd. (BHVN)
NYSE:BHVN
Biohaven Ltd. (BHVN) Stock Price & Analysis
206 Followers
BHVN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$12.35 - $62.21
Previous Close$44.03
Volume1.04M
Average Volume (3M)1.19M
Market Cap
$3.60B
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-7.8
Beta2.38
Next Earnings
May 10, 2024EPS Estimate
-$1.55Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.67
Shares Outstanding81,579,914
10 Day Avg. Volume1,157,521
30 Day Avg. Volume1,192,026
Standard Deviation0.42
R-Squared0.19
Alpha0.08
Financial Highlights & Ratios
Price to Book (P/B)8.75
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-7.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$60.14Price Target Upside36.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
Biohaven Ltd. News
PremiumStock Analysis & Ideas
LLY, REGN, BHVN: Which Biotech Stock Offers the Most Upside?
PremiumThe Fly
Biohaven falls -15.9%
PremiumThe Fly
Biohaven falls -4.3%
PremiumThe Fly
Biohaven falls -5.8%
PremiumCompany Announcements
Biohaven’s MoDE Pioneer Updates on BHV-1300 Progress
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesAnalysts are optimistic about a high likelihood of a positive readout for BHV-1300, underpinned by solid preclinical data and initial human trials.
Drug Development ProgressBiohaven's degrader program BHV-1300 demonstrates promising safety and efficacy, potentially making it a preferred treatment for IgG-mediated diseases.
Strategic Business DevelopmentBiohaven's diverse portfolio, including several key catalysts in the pipeline, positions the company for potential breakthroughs and value creation in the upcoming years.
Bears Say
Clinical TrialsInvestor focus on safety data for higher doses and the upcoming MAD study introduces uncertainty regarding the drug's benefit-risk profile.
Drug SafetyConcerns about the high dosage required for BHV-1300 raise questions about potential toxicity, making safety readouts a critical factor in future assessments.
Financial Performance4Q23 burn came in a bit higher than expected, indicating potential financial stress or mismanagement.
---
Ownership Overview
8.51% Insiders
20.02% Mutual Funds
14.13% Other Institutional Investors
57.34% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
BHVN FAQ
What was Biohaven Ltd.’s price range in the past 12 months?
Biohaven Ltd. lowest stock price was $12.35 and its highest was $62.21 in the past 12 months.
What is Biohaven Ltd.’s market cap?
Currently, no data Available
When is Biohaven Ltd.’s upcoming earnings report date?
Biohaven Ltd.’s upcoming earnings report date is May 10, 2024 which is in 22 days.
How were Biohaven Ltd.’s earnings last quarter?
Biohaven Ltd. released its earnings results on Feb 29, 2024. The company reported -$1.81 earnings per share for the quarter, missing the consensus estimate of -$1.411 by -$0.399.
Is Biohaven Ltd. overvalued?
According to Wall Street analysts Biohaven Ltd.’s price is currently Undervalued.
Does Biohaven Ltd. pay dividends?
Biohaven Ltd. does not currently pay dividends.
What is Biohaven Ltd.’s EPS estimate?
Biohaven Ltd.’s EPS estimate is -$1.55.
How many shares outstanding does Biohaven Ltd. have?
Biohaven Ltd. has 81,661,510 shares outstanding.
What happened to Biohaven Ltd.’s price movement after its last earnings report?
Biohaven Ltd. reported an EPS of -$1.81 in its last earnings report, missing expectations of -$1.411. Following the earnings report the stock price went up 2.908%.
Which hedge fund is a major shareholder of Biohaven Ltd.?
Among the largest hedge funds holding Biohaven Ltd.’s share is Perceptive Advisors LLC. It holds Biohaven Ltd.’s shares valued at 74M.
---
Biohaven Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$60.14 (36.59% Upside)
$60.14 (36.59% Upside)
Blogger Sentiment
Bullish
BHVN Sentiment 80%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 1.6M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 16.5%
Last 30 Days ▲ 16.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
208.54%
12-Months-Change
Fundamentals
Return on Equity
-84.44%
Trailing 12-Months
Asset Growth
-22.45%
Trailing 12-Months
Company Description
Biohaven Ltd.
Biohaven Ltd is a commercial-stage biopharmaceutical company with a portfolio of innovative therapies to improve the lives of patients with debilitating neurological and neuropsychiatric diseases, including rare disorders. Biohaven's Neuroinnovation portfolio includes FDA-approved Nurtec ODT (rimegepant) for the acute and preventive treatment of migraine (EMA-approved as Vydura (rimegepant) for the acute treatment of migraine with or without aura, and prophylaxis of episodic migraine.
---
BHVN Stock 12 Months Forecast
Average Price Target
$60.14
▲(36.59% Upside)
Technical Analysis
Best Analysts Covering BHVN
1 Year
1 Year Success Rate
7/8 ratings generated profit
1 Year Average Return
+129.57%
reiterated a buy rating last month
Copying Marc Goodman's trades and holding each position for 1 Year would result in 87.50% of your transactions generating a profit, with an average return of +129.57% per trade.
---